Panel Discussion: Choosing Build vs. Buy for Sample Tracking Technology & Making Either Work at Scale

• Weighing custom-built platforms against off-the-shelf LIMS and sample tracking software to match technology investment to trial complexity and organizational maturity
• Confronting Integration Reality: Connecting sample tracking systems with CTMS, LIMS, and central lab databases without creating new data silos
• Debating who owns technology decisions, translational science or clinical operations, and how that ownership shapes adoption and long-term scalability

Moderated by:

Speakers:

Narasimha Marella

Associate Vice President, Clinical Biomarker & Diagnostics Operations

Eli Lilly & Co.

Alyssa Masciarelli

Manager, Biomarker Operations

Bicycle Therapeutics plc

Medha Kamat

Director, Oncology Biomarker & Diagnostic Operations

Johnson & Johnson

Jonathan Saunders

Senior Director, Biomarker Operations

Moderna